BioSpace News Archive

Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today hosted a Key Opinion Leader (KOL) webinar and provided an update on the Company’s ongoing Phase 3 program evaluating once-daily Diazoxide Choline Controlled Release (DCCR) tablets for the treatment of Prader-Willi Syndrome (PWS).

Mydecine Innovations Group Inc. (the “Company”) (CSE:MYCO | OTC:MYCOF) (FSE: 0NFA) announces it has filed amended and restated unaudited condensed interim consolidated financial statements for the nine-month period ended September 30, 2020

Celltrion Group today announced that the Korean Ministry of Food and Drug Safety (MFDS) granted a Conditional Marketing Authorisation (CMA) for the emergency use of Regdanvimab (CT-P59), an anti-COVID-19 monoclonal antibody treatment candidate

There’s no end to the number of times that you hear the message that life is worth living. Constantly repeated phrases like “you only live once” have combined with traditional mantras like “carpe diem” to foster a culture that loves to be in the present.

Enlivant (“Company”) and its Board of Directors announced today that Jack R. Callison, Jr. will be assuming the role of Chairman of Enlivant’s Board of Directors and has resigned as Enlivant’s Chief Executive Officer, effective March 31, 2021

InMed Pharmaceuticals Inc. today announced that it has entered into definitive agreements with certain institutional investors to raise aggregate gross proceeds of approximately US$4.5 million at a price of US$4.25 per unit in a private placement of its equity securities.

Itamar Medical Ltd. (“Itamar Medical” or the “Company”) (Nasdaq: ITMR) (TASE: ITMR), a medical technology company focused on the development and commercialization of non-invasive medical devices to aid in the diagnosis of respiratory sleep disorders, today announced the pricing of its public offering of 3,049,130 American Depositary Shares (“ADSs”) at a public offering price of $22.75 per ADS.

EastWest Bioscience (the “Company” or “EastWest”) (TSXV:EAST) announces, subject to its stock option plan, the grant of 1,720,000 stock options to certain directors, officers, employees and consultants issued pursuant to the Company’s stock option plan.

The Feinstein Institutes for Medical Research will host Driving Responsible Conduct of Research During a Pandemic, a virtual conference highlighting the challenges and lessons learned in conducting high quality, ethical clinical and translational research during a pandemic. The conference i

Physicians with the Texas Cardiac Arrhythmia Institute (TCAI) at St. David’s Medical Center are among the first in the world to participate in a clinical trial to evaluate a new esophageal protection device designed to make ablation procedures safer for patients with atrial fibrillation (A Fib)